Gene Therapy Restores Hearing in Deaf Patients

A Single Shot Changes Everything

A groundbreaking gene therapy has restored hearing in every patient treated in a clinical trial targeting hereditary deafness — some within just weeks of receiving a single injection into the inner ear. The results, published in Nature Medicine, mark a pivotal advance in treating genetic hearing loss and signal the dawn of a new era for the estimated 26 million people worldwide affected by congenital deafness.

How the Therapy Works

The trial, led by Maoli Duan of Sweden's Karolinska Institutet in collaboration with hospitals in China, focused on patients with mutations in the OTOF gene. This gene produces otoferlin, a protein essential for transmitting sound signals from the inner ear's hair cells to the brain. Without it, patients are born profoundly deaf.

Researchers used a synthetic adeno-associated virus (AAV) to deliver a functional copy of the OTOF gene directly into the cochlea through a single injection via the round window membrane — a thin barrier at the base of the inner ear. The procedure requires no repeated dosing.

Dramatic Results Across All Ages

All ten patients — aged 1 to 24 and treated across five Chinese hospitals — showed measurable hearing improvement. The average threshold for detectable sound dropped from 106 decibels to 52 decibels after six months, a shift from near-total deafness to the ability to hear normal conversation.

Most patients began recovering hearing within a single month. Children aged five to eight responded most dramatically. One seven-year-old girl regained nearly complete hearing and was holding everyday conversations within four months of treatment.

"This is a huge step forward in the genetic treatment of deafness, one that can be life-changing for children and adults," Duan said.

Safety and Tolerability

The therapy was well-tolerated across all age groups. The most common side effect was a temporary decrease in neutrophils, a type of white blood cell. No serious adverse reactions were reported during the six- to twelve-month follow-up period.

A Growing Field of Competition

The Chinese-Swedish trial is not alone. Pharmaceutical giant Regeneron has reported similarly striking results from its CHORD trial of a therapy called DB-OTO, also targeting OTOF-related deafness. Published in the New England Journal of Medicine, the CHORD data showed that 11 of 12 children treated experienced clinically meaningful hearing gains, with three achieving normal hearing levels. Regeneron plans to file for U.S. FDA approval.

The parallel success of multiple programs underscores both the robustness of the AAV-based approach and the urgency of the unmet medical need.

Beyond OTOF: The Road Ahead

OTOF mutations account for only a fraction of hereditary hearing loss. Researchers are now expanding their sights to more common deafness-causing genes, including GJB2 — responsible for roughly half of all genetic hearing loss — and TMC1. Animal studies targeting these genes have already shown promising results.

If those efforts succeed, gene therapy could eventually address the majority of the roughly 200 genes linked to hereditary deafness, transforming treatment from hearing aids and cochlear implants to one-time biological cures.